title: Glutathione S-transferase T1, O1 and O2 polymorphisms are associated with survival in muscle invasive bladder cancer patients.
abstract: OBJECTIVE
  To examine the association of six glutathione transferase (GST) gene polymorphisms (GSTT1, GSTP1/rs1695, GSTO1/rs4925, GSTO2/rs156697, GSTM1, GSTA1/rs3957357) with the survival of patients with muscle invasive bladder cancer and the genotype modifying effect on chemotherapy.
  
  
  METHODS
  A total of 105 patients with muscle invasive bladder cancer were included in the study. The follow-up lasted 5 years. The effect of GSTs polymorphisms on predicting mortality was analyzed by the Cox proportional hazard models, while Kaplan-Meier analysis was performed to assess differences in survival.
  
  
  RESULTS
  GSTT1 active, GSTO1 Asp140Asp or GSTO2 Asp142Asp genotypes were independent predictors of a higher risk of death among bladder cancer patients (HR = 2.5, P = 0.028; HR = 2.9, P = 0.022; HR = 3.9, P = 0.001; respectively) and significantly influenced the overall survival. There was no association between GSTP1, GSTM1 and GSTA1 gene variants with overall mortality. Only GSTO2 polymorphism showed a significant effect on the survival in the subgroup of patients who received chemotherapy (P = 0.006).
  
  
  CONCLUSIONS
  GSTT1 active genotype and GSTO1 Asp140Asp and GSTO2 Asp142Asp genotypes may have a prognostic/pharmacogenomic role in patients with muscle invasive bladder cancer.
authors.affiliation: Institute of Medical and Clinical Biochemistry, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
authors.forename: Tatjana I
authors.initials: TI
authors.lastname: Djukic
authors.forename: Ana R
authors.initials: AR
authors.lastname: Savic-Radojevic
authors.forename: Tatjana D
authors.initials: TD
authors.lastname: Pekmezovic
authors.forename: Marija G
authors.initials: MG
authors.lastname: Matic
authors.forename: Marija S
authors.initials: MS
authors.lastname: Pljesa-Ercegovac
authors.forename: Vesna M
authors.initials: VM
authors.lastname: Coric
authors.forename: Tanja M
authors.initials: TM
authors.lastname: Radic
authors.forename: Sonja R
authors.initials: SR
authors.lastname: Suvakov
authors.forename: Biljana N
authors.initials: BN
authors.lastname: Krivic
authors.forename: Dejan P
authors.initials: DP
authors.lastname: Dragicevic
authors.forename: Tatjana P
authors.initials: TP
authors.lastname: Simic
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D005260:Female; D005838:Genotype; D005982:Glutathione Transferase / Q000235:genetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D011379:Prognosis; D016016:Proportional Hazards Models; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality*
chemical_list: D000970:Antineoplastic Agents; C413545:glutathione S-transferase T1; C490476:GSTO1 protein, human; C492569:GSTO2 protein, human; D005982:Glutathione Transferase
references.citation: Ann Oncol. 2012 Jul;23(7):1750-6
references.pmid: 22052985
references.citation: Urol Oncol. 2011 Jan-Feb;29(1):70-7
references.pmid: 19162514
references.citation: Pharmacogenet Genomics. 2010 Aug;20(8):507-15
references.pmid: 20577141
references.citation: Pharmacogenomics J. 2004;4(3):143-53
references.pmid: 15024382
references.citation: Histol Histopathol. 2006 Nov;21(11):1199-207
references.pmid: 16874663
references.citation: Cancer Lett. 2006 May 18;236(2):276-81
references.pmid: 15992993
references.citation: Mol Neurodegener. 2012 Apr 11;7:13
references.pmid: 22494505
references.citation: Dis Markers. 2010;29(2):81-7
references.pmid: 21045267
references.citation: Mol Pharm. 2011 Oct 3;8(5):1698-708
references.pmid: 21851097
references.citation: J Nutr. 2007 Oct;137(10):2171-84
references.pmid: 17884994
references.citation: Methods Enzymol. 2005;401:78-99
references.pmid: 16399380
references.citation: Pharmacogenomics J. 2011 Aug;11(4):292-9
references.pmid: 20514077
references.citation: Free Radic Biol Med. 2013 Jan;54:62-70
references.pmid: 23142420
references.citation: Eur Urol. 2007 Aug;52(2):470-7
references.pmid: 17267100
references.citation: Nephrol Dial Transplant. 2013 Jan;28(1):202-12
references.pmid: 23034843
references.citation: Annu Rev Pharmacol Toxicol. 2005;45:51-88
references.pmid: 15822171
references.citation: J Natl Cancer Inst. 2002 Jun 19;94(12):936-42
references.pmid: 12072547
references.citation: Sci Total Environ. 2011 Jan 1;409(3):465-70
references.pmid: 21094982
references.citation: Biochem J. 2002 Jun 1;364(Pt 2):441-7
references.pmid: 12023887
references.citation: Urology. 1997 Apr;49(4):644-51
references.pmid: 9111645
references.citation: Cancer Res. 2005 May 1;65(9):3751-61
references.pmid: 15867371
references.citation: Int J Med Sci. 2011;8(6):492-500
references.pmid: 21897762
references.citation: J Drug Target. 2007 Aug-Sep;15(7-8):475-86
references.pmid: 17671894
references.citation: Nat Rev Urol. 2009 May;6(5):281-9
references.pmid: 19424176
references.citation: Urology. 2005 May;65(5):1035-40
references.pmid: 15882759
references.citation: Toxicol Lett. 2012 Apr 5;210(1):100-6
references.pmid: 22306368